Contact Us | Print Page | Sign In | Register
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 9 of 10
 |<   <<   <  4  |  5  |  6  |  7  |  8  |  9  |  10

Industry News for MS (INforMS)
Thursday, October 8, 2015   (0 Comments - view/add)
CMSC INforMS: Results from ZINBRYTA Phase 3 DECIDE Study Presented at ECTRIMS »
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon B...
Wednesday, October 7, 2015   (0 Comments - view/add)
CMSC INforMS: New Analysis Suggests Aubagio Slows Brain Atrophy in People with Relapsing MS »
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis Add...
Wednesday, October 7, 2015   (0 Comments - view/add)
CMSC INforMS: Data Show Effects of TECFIDERA in Newly-Diagnosed and Early Disease Course MS Patients »
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course...
Tuesday, October 6, 2015   (0 Comments - view/add)
CMSC INforMS: Opexa Announces Granting of New T-cell Patents Covering Tcelna »
Opexa Announces Granting of New T-cell Patents Covering Tcelna®; Patent Estate Increases to 160 Issued Patents 10/06...
Monday, October 5, 2015   (0 Comments - view/add)
CMSC INforMS: Genzyme Introduces "vs.MS", a Global Initiative »
Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better In...
Sunday, September 27, 2015   (0 Comments - view/add)
CMSC INforMS: Genentech’s Ocrelizumab to Show Efficacy in People with PPMS in Large Phase III Study »
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclero...
Friday, September 25, 2015   (0 Comments - view/add)
CMSC INforMS: Bayer Receives FDA Approval for BETACONNECT »
Bayer Receives FDA Approval for BETACONNECT – First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Scler...
Friday, August 21, 2015   (0 Comments - view/add)
CMSC INforMS: Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for MS »
Novartis acquires all remaining rights to GSK’s Ofatumumab to develop treatments for MS and other autoimmune indications...
Monday, August 3, 2015   (0 Comments - view/add)
CMSC INforMS: Pfizer & Synthon Enter Into U.S. Commercialization Agreement for Treatment of MS »
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis S...
Tuesday, July 28, 2015   (0 Comments - view/add)
CMSC INforMS: FDA: Gadolinium-based MRI Contrast Agents Pose Possible Brain Risk »
A statement from our CMSC leadership: While the implications for MS patient care may need to be re-evaluated and changed...
Monday, June 29, 2015   (0 Comments - view/add)
CMSC INforMS: Genentech’s ocrelizumab Reduced Both Relapses and Disability Progression versus Rebif »
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif&re...
Thursday, June 18, 2015   (0 Comments - view/add)
CMSC INforMS: Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg »
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-a...
Tuesday, June 9, 2015   (0 Comments - view/add)
CMSC INforMS: Novartis Statement on Reported Case of PML »
Novartis Statement on Reported Case of PML Novartis has been informed of a patient with progressive multifocal leukoence...
Wednesday, April 29, 2015   (0 Comments - view/add)
CMSC INforMS: FDA Accepts Biologics License Application for ZINBRYTA for Treatment of MS »
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS BLA Accepta...
Friday, April 24, 2015   (0 Comments - view/add)
CMSC INforMS: Mallinckrodt Research Fellowship Award Program Announcement »
Mallinckrodt Research Fellowship Award Program Announcement Mallinckrodt Pharmaceuticals is pleased to announce the Rese...
Wednesday, April 22, 2015   (0 Comments - view/add)
CMSC INforMS: FDA Accepts Filing of BETACONNECT for RRMS Patients Taking BETASERON »
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon...
Tuesday, April 21, 2015   (0 Comments - view/add)
CMSC INforMS: International Survey Identifies Opportunities for Improving MS Treatment Satisfaction »
International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction Many Factors Influen...
Tuesday, April 21, 2015   (0 Comments - view/add)
CMSC INforMS: PLEGRIDY Three-Year Data Support Long-Term Safety and Efficacy in MS Patients »
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficac...
Monday, April 20, 2015   (0 Comments - view/add)
CMSC INforMS: TECFIDERA Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients »
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients TECFIDERA...
Thursday, April 16, 2015   (0 Comments - view/add)
CMSC INforMS: The FDA Approves a Generic form of Copaxone »
The FDA Approves a Generic form of Copaxone® Thursday, April 16, 2015 The U.S. Food and Drug Administration has a...
Friday, March 27, 2015   (0 Comments - view/add)
EMA Validates Marketing Authorisation Application for ZINBRYTA for Treatment of MS »
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for...
Monday, March 9, 2015   (0 Comments - view/add)
CMSC INforMS: EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna for MS »
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis...
Monday, March 2, 2015   (0 Comments - view/add)
CMSC INforMS: Teva Neuroscience & Access Health Team Up for Special MS Awareness Show: Thursday, 3/5 »
Teva Neuroscience & Access Health Team Up for Special MS Awareness Show: Thursday, March 5 As Multiple Sclerosis Awa...
Monday, February 2, 2015   (0 Comments - view/add)
CMSC INforMS: Acorda Announces Data from First Clinical Trial of Remyelinating Antibody in MS »
Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis...
Wednesday, December 3, 2014   (0 Comments - view/add)
CMSC INforMS: First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval »
First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval – Lemtrada now available in the U.S. t...
Friday, November 14, 2014   (0 Comments - view/add)
CMSC INforMS: Genzyme’s Lemtrada Approved by the FDA »
Genzyme’s Lemtrada Approved by the FDA - Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Pro...
Tuesday, November 4, 2014   (0 Comments - view/add)
CMSC INforMS: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in RRMS »
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis T...
Monday, October 20, 2014   (0 Comments - view/add)
CMSC INforMS: Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio »
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio Once-daily Aubagio is the only oral treatm...
Thursday, September 11, 2014   (0 Comments - view/add)
CMSC INforMS: At 4 Yrs, Treatment Effect Maintained in Patients Who Received Lemtrada in Studies »
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal...
Wednesday, September 10, 2014   (0 Comments - view/add)
CMSC INforMS: New Intl Survey Finds MS Patients and Neurologists View Communication Positively »
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS...
Friday, August 15, 2014   (0 Comments - view/add)
CMSC INforMS: Biogen Idec’s PLEGRIDY Approved in the US for the Treatment of MS »
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis Friday, Augus...
Wednesday, July 23, 2014   (0 Comments - view/add)
CMSC INforMS: PLEGRIDY (Peginterferon beta-1a) Approved in the EU for the Treatment of MS »
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Wednesday, Jul...
Thursday, July 3, 2014   (0 Comments - view/add)
CMSC INforMS: Teva files Citizen Petition with the US FDA regarding the Complexity of COPAXONE »
Teva files Citizen Petition with the U.S. Food and Drug Administration (FDA) regarding the Complexity of COPAXONE® (Gl...
Monday, June 30, 2014   (0 Comments - view/add)
CMSC INforMS: Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis »
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis Monday, June 30, 2014 8:00 am EDT CAMBRI...
Monday, June 16, 2014   (0 Comments - view/add)
CMSC INforMS: Biogen Idec and AbbVie Announce Results from Phase 3 Study Investigating Daclizumab »
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process i...

Displaying page 9 of 10
 |<   <<   <  4  |  5  |  6  |  7  |  8  |  9  |  10

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275

info@mscare.org